Another interview taken from the BioProcess International Theater at BIO, in June 2022. This time, I sat down with Brian Finrow, the Co-Founder and CEO of Lumen Biosciences - a biotech looking to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology. The firm is developing ‘oral antibodies’ using its platform based on spirulina – the protein-rich cyanobacteria touted by many health enthusiasts as a ‘superfood’ – to create tiny factories that churn out therapeutic antibodies.